Test for cancer
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Advances in Multi-Cancer Detection Tests
Introduction to Multi-Cancer Detection (MCD) Tests
Early detection of cancer significantly improves treatment outcomes and survival rates. Recent advancements in multi-cancer detection (MCD) tests, particularly those utilizing blood-based biomarkers, have shown promise in identifying various cancer types at early stages. These tests primarily focus on detecting circulating tumor DNA (ctDNA) and other molecular markers in the blood.
CancerSEEK: A Multi-Analyte Blood Test
One of the notable advancements in MCD is the CancerSEEK test, which combines protein biomarkers and tumor-specific mutations in circulating DNA. This test has demonstrated the ability to detect eight common cancer types, including ovarian, liver, stomach, pancreatic, esophageal, colorectal, lung, and breast cancers. In a study involving 1005 patients with nonmetastatic cancers, CancerSEEK achieved a sensitivity range of 69% to 98% and a specificity greater than 99%. This high specificity indicates a low rate of false positives, making CancerSEEK a reliable tool for early cancer detection.
Cell-Free DNA-Based Multi-Cancer Early Detection (MCED) Tests
MCED tests, which detect cell-free tumor DNA (cfDNA) in the blood, have emerged as a potential tool for reducing cancer morbidity and mortality. A systematic review of these tests revealed a median sensitivity of 73% and specificity generally above 95% across various studies. Sensitivity tends to increase with the stage of cancer, highlighting the importance of these tests in early detection and diagnosis.
MNR: Multi Normalized Ratio Test
Another promising approach is the Multi Normalized Ratio (MNR) test, which evaluates various cfDNA parameters using a q-PCR based method. This test has shown a discriminative potential of 100% between normal and cancer cell lines in preliminary studies. When applied to plasma samples, the MNR test achieved an area under the curve (AUC) of 0.81, with a sensitivity of 70% and specificity of 77%. Combining MNR with total cfDNA concentration and fragmentation biomarkers further improved sensitivity and specificity, making it a robust tool for early cancer detection.
Performance of Methylation-Based Assays
Methylation-based assays, such as the one developed by Grail, have also shown promise in detecting early-stage cancers. These assays can identify the tissue of origin with an accuracy of 90.2% and detect 55.1% of cancers across various types and stages. Such high accuracy in identifying the tissue of origin is crucial for guiding subsequent diagnostic and therapeutic interventions.
Real-World Trials and Clinical Validation
Real-world trials have validated the effectiveness of these blood tests in large populations. For instance, a study involving nearly 10,000 women without known cancer detected 26 tumors using a blood test, confirming the test's potential in a general population setting. Similarly, a Vietnamese cohort study demonstrated the clinical application of a multi-cancer blood test, achieving a positive predictive value of 60% and 83.3% accuracy in detecting tumor location.
Conclusion
The development and validation of multi-cancer detection tests represent a significant advancement in oncology. These tests, particularly those based on ctDNA and methylation assays, offer high specificity and moderate to high sensitivity, making them valuable tools for early cancer detection. As these tests continue to be refined and validated in larger, diverse populations, they hold the potential to transform cancer screening and improve patient outcomes through earlier diagnosis and treatment.
Sources and full results
Most relevant research papers on this topic